Compared to unmodified CIKs, CAR-engineered counterparts exhibited improved tumor control and were associated with selective accumulation of NK and T-NK subpopulations at tumor sites, suggesting the enhanced engagement of innate immune mechanisms. This evidence concerns the gene TRAF3IP2 and neoplasm.